Kodiak Sciences (KOD) Climbs 75% on Stellar Clinical Results

What: Kodiak Sciences (KOD) shares have surged **75%** after announcing stellar clinical results for its lead product.
Why: The company's treatment for a rare eye disease has shown significant improvement in patient outcomes.
Signal: The strong clinical data has sent a positive signal to investors, boosting the stock's value.
Target: KOD is now targeting a market capitalization of over **$5 billion**.
Risk: However, the company still faces regulatory risks and competition from established players in the eye care market.